Table 3.
Patient treatment-related adverse events
| Adverse Events | Any level of adverse event | Grade 3 adverse events | ||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||
| TACE + Lenvatinib + PD-1 (n=61) | HAIC + Lenvatinib + PD1 (n=34) | X2 Value | P Value | TACE + Lenvatinib + PD-1 (n=61) | HAIC + Lenvatinib + PD-1 (n=34) | X2 Value | P Value | |
| Leukopenia | 10 (16.4%) | 12 (35.3%) | 4.383 | 0.036 | 0 | 2 (5.9%) | - | 0.126 |
| Thrombocytopenia | 6 (9.8%) | 7 (20.6%) | 2.137 | 0.144 | 0 | 2 (5.9%) | - | 0.126 |
| Rash | 8 (13.1%) | 5 (14.7%) | 0.047 | 0.829 | 0 | 0 | - | - |
| Itchy skin | 6 (9.8%) | 4 (11.8%) | - | 0.742 | 0 | 0 | - | - |
| Hand-foot syndrome | 20 (32.8%) | 10 (29.4%) | 0.115 | 0.734 | 2 (3.3%) | 0 | - | 0.535 |
| ALT and AST level increase | 38 (62.3%) | 15 (44.1%) | 2.619 | 0.106 | 0 | 0 | - | - |
| Serum bilirubin increase | 25 (41.0%) | 7 (20.6%) | 4.065 | 0.044 | 4 (6.6%) | 1 (2.9%) | - | 0.652 |
| Diarrhea | 8 (13.1%) | 5 (14.7%) | 0.047 | 0.829 | 2 (3.3%) | 1 (2.9%) | - | 1.000 |
| Nausea/Vomit | 14 (23.0%) | 15 (44.1%) | 4.612 | 0.032 | 0 | 0 | - | - |
| Proteinuria | 14 (23.0%) | 7 (20.6%) | 0.071 | 0.790 | 0 | 0 | - | - |
| Hypothyroidism | 15 (24.6%) | 9 (26.5%) | 0.041 | 0.840 | 1 (1.6%) | 0 | 1.000 | |
| Gastrointestinal bleeding | 6 (9.8%) | 2 (5.9%) | - | 0.707 | 6 (9.8%) | 2 (5.9%) | - | 0.707 |
| Stomach ache | 26 (42.6%) | 11 (32.4%) | 0.968 | 0.325 | 4 (6.6%) | 2 (5.9%) | - | 1.000 |
| Hair loss | 6 (9.8%) | 4 (11.8%) | - | 0.742 | 0 | 0 | - | - |
| Weight decreased | 10 (16.4%) | 5 (14.7%) | 0.047 | 0.829 | 0 | 0 | - | - |
| Decrease appetite | 24 (39.3%) | 16 (47.1%) | 0.533 | 0.465 | 0 | 0 | - | - |
| Fatigue | 26 (42.6%) | 13 (38.2%) | 0.174 | 0.677 | 0 | 0 | - | - |
| Hypertension | 23 (37.7%) | 14 (41.2%) | 0.111 | 0.739 | 4 (6.6%) | 3 (8.8%) | - | 0.698 |
ALT: Alanine aminotransferase; AST: Aspartate transaminase.